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vealed the molecular mechanism by which these inter-Finding Specificity within
actions are regulated by hormones [5]. Biochemicala Conserved Interaction Site studies have demonstrated the feasibility of blocking the
interaction between nuclear receptors and coactivators
with the help of small peptides containing the LxxLL
interaction motif [8–11]. These results suggest a possi-
Recently developed approaches to generate drugs ble hormone-independent mechanism for regulating the
that regulate hormone-induced gene activation focus transcriptional activity of nuclear receptors and move
on modulating the interaction of nuclear receptors the interaction of coregulators with the hydrophobic
with coactivators. A study by Geistlinger and Guy [1] groove into the spotlight for drug design.
demonstrates the feasibility of this approach and pro- The Specificity of Nuclear
vides surprising evidence for specificity within the Receptor:Coactivator Interactions Relies
conserved nuclear receptor:coactivator interaction on Receptor-Specific Surfaces
surface. To be useful therapeutic agents, inhibitors that block the
interaction between nuclear receptors and coregulators
Many important developmental and physiological pro- need to be both receptor and coregulator specific. The
cesses are regulated by hormones that act through interaction surfaces between nuclear receptors and co-
members of the conserved nuclear receptor family [2]. activators, however, are highly conserved (Figure 2), and
These receptors are intracellular transcription factors it is not obvious how these interactions could be dis-
that change the expression of hormone-responsive tar- rupted selectively.
get genes. Due to their involvement in a broad range of Reporter analyses in cultured mammalian cells and
common diseases, including breast and prostate can- “knock out” studies in mice have revealed that nuclear
cer, arthritis, obesity, and diabetes, nuclear receptors receptor:coactivator interactions are, at least to some
have advanced to become one of the top targets of degree, selective [12–15]. Comparative structural and
basic and pharmaceutical research. Thus far, most drug sequence analyses showed that while the coactivator
design efforts have been focused on the development of LxxLL motif and the interior of the nuclear receptor hy-
antagonists, synthetic ligands that compete with natural drophobic groove are highly conserved, the sequences
hormones and block the ability of nuclear receptors to adjacent to the LxxLL motif and the structure of the rim of
regulate transcription. Although in some cases it has the groove are variable. Peptide competition experiments
been possible to identify nuclear receptor antagonists and site-directed mutagenesis approaches exploring
that act tissue specifically, generally it has been difficult these differences confirmed their ability in modulating the
to separate pathological activities of these receptors in affinity of nuclear receptor:coactivator interactions
one tissue from their beneficial effects in other tissues. [8–11]. Other results suggested that some nuclear re-
Thus, while many antagonists are valuable therapeutic ceptor:coactivator interactions are stabilized by addi-
agents in the treatment of hormone-dependent dis- tional interaction surfaces [16–18]. While these results
eases, their use is often associated with unwanted side were promising, they indicated that it might be difficult
effects. Hence, the identification of alternative strategies to find a general strategy to develop small molecules
to regulate the transcriptional activity of nuclear recep- that disrupt these interactions specifically.
tors has become of increasing interest. Conserved Nuclear Receptor:Coactivator
The Nuclear Receptor:Coregulator Interaction Interaction Surfaces Can Be Disrupted
Site as a New Drug Target Receptor Specifically
Recent structural and functional studies have revealed The recently published study by Geislinger and Guy [1]
the molecular mechanisms by which nuclear receptors brings an unexpected turn to this story by demonstrating
regulate transcription [3]. The breakthrough came with the feasibility of developing selective inhibitors for even
the discovery that hormone binding regulates the inter- the conserved LxxLL:hydrophobic groove interaction it-
action of nuclear receptors with coregulators that in- self. Guided by in silico docking experiments using exist-
crease (coactivators) or decrease (corepressors) the ex- ing crystal structures of human estrogen (hER) and thy-
pression of hormone-responsive genes. Although many roid hormone receptor (hTR) coactivator complexes [7,
of these coregulators are structurally and functionally 8], Geislinger and Guy produced a library of 87 potential
diverse, their interaction with nuclear receptors is often proteomimetics of a particular coactivator LxxLL inter-
mediated by short amphipathic  helices that, in the action motif in which conserved leucine residues are
case of coactivators, contain a conserved LxxLL se- individually replaced with nonnatural amino acids. Fluo-
quence motif (L is leucine, x is any amino acid) [4]. rescence polarization equilibrium competition assays
Crystallographic analyses showed that the hydrophobic using these compounds revealed that 71 of the 87 com-
leucine residues in this motif interact with a shallow, pounds bind hER and hTR with affinity equal to or higher
solvent-exposed hydrophobic groove in the nuclear re- than the original LxxLL interaction motif. An astonishing
ceptor ligand binding domain (LBD) (Figure 1) [5–8]. The finding was that many of these compounds are selective
identification of anhelix that changes the conformation for particular nuclear receptors: 12 of the identified com-
pounds were between 10- and 600-fold selective forof this groove in response to hormone binding has re-
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the receptor, tissue, and promoter specificity of coacti-
vators. As this knowledge evolves, the ability to inhibit
these interactions specifically will pave the road to novel
and more refined therapies for hormone-dependent dis-
eases.
Figure 2. The Hydrophobic Groove of Nu-
clear Receptors Is Highly Conserved
The hydrophobic groove in the nuclear recep-
tor ligand binding binding domain is formed
by residues of  helices 3 (H3), 4 (H4), 5 (H5),
and 12 (H12) [6–8]. Shown is an alignment of
the corresponding sequences of the human
thyroid hormone receptors (hTR, hTR) and
estrogen receptors (hER, hER). Residues that form the hydrophobic groove are shaded. Groove residues that are variant are labeled with
an asterisk. Most replacements of these residues are conservative.
